• Valion Bio reported positive preclinical safety results for Entolimod, supporting further development as a treatment for acute radiation syndrome.
• The U.S. government-funded study involved 20 male mice and assessed a single 0.72 mg/kg subcutaneous dose over 14 days.
• Treated animals maintained stable body weights, with no significant treatment-related differences in blood counts or organ function measures versus saline controls.
• The Armed Forces Radiobiology Research Institute plans a fully funded efficacy study evaluating survival and gastrointestinal recovery with treatment following radiation exposure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610280745ACCESSWRNAPR_____1242999) on October 28, 2026, and is solely responsible for the information contained therein.